Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trex: Regulatory T cell therapy + tocilizumab + donor bone marrow in HLA-mismatched living donor kidney transplantation
2018-003142-16Phase 2Active
- Sponsor
- Medical University of Vienna
- Start
- Oct 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of expanded regulatory T cells and tocilizumab in kidney transplant and organ allograft rejection, sponsored by Medical University of Vienna. Primary endpoint: Co-primary endpoint 1 (safety): incidence of GVHD, impaired graft function or death within 12 months. Started Oct 2018; status: active.
02
Drugs
expanded regulatory T cellstocilizumab
03
Conditions
kidney transplantorgan allograft rejection
Beyond the preview
Go deeper on 2018-003142-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003142-16.